|
1.
|
Kyle RA and Rajkumar SV: Multiple myeloma.
New Engl J Med. 351:1860–1873. 2004. View Article : Google Scholar
|
|
2.
|
Talamo G, Farooq U, Zangari M, et al:
Beyond the CRAB symptoms: a study of presenting clinical
manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk.
10:464–468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Myeloma Trialists’ Collaborative group:
Combination chemotherapy versus melphalan plus prednisone as
treatment for multiple myeloma: An overview of 6,633 patients from
27 randomized trials. J Clin Oncol. 16:3832–3842. 1998.PubMed/NCBI
|
|
4.
|
Bladé J, Rosiñol L, Cibeira MT, Rovira M
and Carreras E: Hematopoietic stem cell transplantation for
multiple myeloma beyond 2010. Blood. 115:3655–3663. 2010.PubMed/NCBI
|
|
5.
|
Anderson KC, Alsina M, Bensinger W, et al:
Multiple myeloma. J Natl Compr Canc Netw. 9:1146–1183. 2011.
|
|
6.
|
Brenner H, Gondos A and Pulte D: Recent
major improvement in long-term survival of younger patients with
multiple myeloma. Blood. 111:2521–2526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Lahuerta JJ, Mateos MV, Martínez-López J,
et al: Influence of pre- and post-transplantation responses on
outcome of patients with multiple myeloma: sequential improvement
of response and achievement of complete response are associated
with longer survival. J Clin Oncol. 26:5775–5782. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Barlogie B, Tricot G, Anaissie E, et al:
Thalidomide and hematopoietic-cell transplantation for multiple
myeloma. N Engl J Med. 354:1021–1030. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Barlogie B, Pineda-Roman M, van Rhee F, et
al: Thalidomide arm of Total Therapy 2 improves complete remission
duration and survival in myeloma patients with metaphase
cytogenetic abnormalities. Blood. 112:3115–3121. 2008. View Article : Google Scholar
|
|
10.
|
Harousseau JL and Moreau P: Autologous
hematopoietic stem-cell transplantation for multiple myeloma. N
Engl J Med. 360:2645–2654. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
van de Velde HJ, Liu X, Chen G, Cakana A,
Deraedt W and Bayssas M: Complete response correlates with
long-term survival and progression-free survival in high-dose
therapy in multiple myeloma. Haematologica. 92:1399–1406.
2007.PubMed/NCBI
|
|
12.
|
Harousseau JL, Attal M, Avet-Loiseau H, et
al: Bortezomib plus dexamethasone is superior to vincristine plus
doxorubicin plus dexamethasone as induction treatment prior to
autologous stem-cell transplantation in newly diagnosed multiple
myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol.
28:4621–4629. 2010. View Article : Google Scholar
|
|
13.
|
Cavo M, Zamagni E, Tosi P, et al:
Superiority of thalidomide and dexamethasone over
vincristine-doxorubicindexamethasone (VAD) as primary therapy in
preparation for autologous transplantation for multiple myeloma.
Blood. 106:35–39. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Moreau P, Facon T, Attal M, et al:
Comparison of reduced-dose bortezomib plus thalidomide plus
dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as
induction treatment prior to ASCT in de novo multiple myeloma (MM):
Results of IFM2007-02 study. J Clin Oncol. 28(Suppl 15):
A80142010.
|
|
15.
|
Richardson PG, Weller E, Lonial S, et al:
Lenalidomide, bortezomib, and dexamethasone combination therapy in
patients with newly diagnosed multiple myeloma. Blood. 116:679–686.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Roussel M, Moreau P, Huynh A, et al:
Bortezomib and high-dose melphalan as conditioning regimen before
autologous stem cell transplantation in patients with de novo
multiple myeloma: A phase 2 study of the Intergroupe Francophone du
Myelome (IFM). Blood. 115:32–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Harousseau JL, Attal M and Avet-Loiseau H:
The role of complete response in multiple myeloma. Blood.
114:3139–3146. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Niesvizky R, Richardson PG, Rajkumar SV,
et al: The relationship between quality of response and clinical
benefit for patients treated on the bortezomib arm of the
international, randomized, phase 3 APEX trial in relapsed multiple
myeloma. Br J Haematol. 143:46–53. 2008. View Article : Google Scholar
|
|
19.
|
Harousseau JL, Weber D, Dimopoulos M, et
al: Relapsed /refractory multiple myeloma treated with
lenalidomide/dexamethasone who achieve a complete or near complete
response have longer overall survival and time to progression
compared with patients achieving a partial response. Blood.
110:35982007.
|
|
20.
|
Pineda-Roman M, Zangari M, Haessler J, et
al: Sustained complete remissions in multiple myeloma linked to
bortezomib in total therapy 3: comparison with total therapy 2. Br
J Haematol. 140:625–634. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Spencer A, Prince HM, Roberts AW, et al:
Consolidation therapy with low-dose thalidomide and prednisolone
prolongs the survival of multiple myeloma patients undergoing a
single autologous stem-cell transplantation procedure. J Clin
Oncol. 27:1788–1793. 2009. View Article : Google Scholar
|
|
22.
|
Attal M, Harousseau JL, Leyvraz S, et al:
Maintenance therapy with thalidomide improves survival in patients
with multiple myeloma. Blood. 108:3289–3294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Moreau P, Avet-Loiseau H, Harousseau JL
and Attal M: Current trends in autologous stem-cell transplantation
for myeloma in the era of novel therapies. J Clin Oncol.
29:1898–1906. 2011. View Article : Google Scholar : PubMed/NCBI
|
